Inventor · disambiguated record
Arlene H. Sharpe
Also filed as: SHARPE ARLENE · SHARPE ARLENE H · SHARPE ARLENE HELEN
35 granted patents·26 pending applications·664 citations·filing 1994–2025
97Inventor score
Files withDANA FARBER CANCER INST INC16NOVARTIS AG13HARVARD COLLEGE10UNIV EMORY6BRIGHAM & WOMENS HOSPITAL3
Top patents by PatentIndex Score
61 records- 0199US9683048B2Antibody molecules to PD-1 and uses thereofNOVARTIS AG·Filed 2015·Granted Jun 20, 2017·115 cites·144 claims
- 0298US9815898B2Antibody molecules to PD-1 and uses thereofNOVARTIS AG·Filed 2017·Granted Nov 14, 2017·35 cites·30 claims
- 0397US10851165B2Antibody molecules to PD-L1 and methods of treating cancerNOVARTIS AG·Filed 2018·Granted Dec 1, 2020·10 cites·80 claims
- 0497US9988452B2Antibody molecules to PD-L1 and uses thereofNOVARTIS AG·Filed 2015·Granted Jun 5, 2018·30 cites·27 claims
- 0596US10752687B2Antibody molecules to PD-1 and uses thereofNOVARTIS AG·Filed 2017·Granted Aug 25, 2020·6 cites·90 claims
- 0695US7432059B2Methods of identifying compounds that upmodulate T cell activation in the presence of a PD-1 mediated signalDANA FARBER CANCER INST INC·Filed 2001·Granted Oct 7, 2008·119 cites·13 claims
- 0794US11827704B2Antibody molecules to PD-1 and uses thereofNOVARTIS AG·Filed 2020·Granted Nov 28, 2023·2 cites·43 claims
- 0894US9845356B2Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of useDANA FARBER CANCER INST INC·Filed 2013·Granted Dec 19, 2017·21 cites·30 claims
- 0994US9457080B2Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathwayUNIV EMORY·Filed 2013·Granted Oct 4, 2016·31 cites·16 claims
- 1094US7722868B2Agents that modulate the interaction of B7-1 polypeptide with PD-L1 and methods of use thereofDANA FARBER CANCER INST INC·Filed 2006·Granted May 25, 2010·116 cites·7 claims
- 1194US7619078B2Nucleic acid molecules encoding B7-1DANA FARBER CANCER INST INC·Filed 2006·Granted Nov 17, 2009·17 cites·6 claims
- 1293US8652465B2Methods and compositions for the treatment of persistent infectionsFREEMAN GORDON·Filed 2006·Granted Feb 18, 2014·61 cites·26 claims
- 1390US2025066479A1Antibody molecules to pd-1 and uses thereofNOVARTIS AG·Filed 2024·Application pending·0 cites
- 1489US6608180B2B7-specific antibodiesBRIGHAM & WOMENS HOSPITAL·Filed 2001·Granted Aug 19, 2003·12 cites·2 claims
- 1587US6218510B1B7-1 and B7-2 polypeptidesBRIGHAM & WOMAN S HOSPITAL·Filed 1994·Granted Apr 17, 2001·35 cites·12 claims
- 1686US11413340B2Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapyNOVARTIS AG·Filed 2016·Granted Aug 16, 2022·2 cites·32 claims
- 1786US10934353B2Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of useDANA FARBER CANCER INST INC·Filed 2017·Granted Mar 2, 2021·2 cites·20 claims
- 1886US10202454B2Anti-PD-L1 monoclonal antibodies and fragments thereofDANA FARBER CANCER INST INC·Filed 2014·Granted Feb 12, 2019·4 cites·19 claims
- 1986US2024343808A1Antibody molecules to pg-l1 and methods of treating cancer and infectious diseasesNOVARTIS AG·Filed 2023·Application pending·0 cites
- 2084US10457733B2Agents that modulate immune cell activation and methods of use thereofDANA FARBER CANCER INST INC·Filed 2013·Granted Oct 29, 2019·4 cites·18 claims
- 2184US6294660B1Nucleic acids encoding B7-1 and B7-2 moleculesDANA FARBER CANCER INST BRIGHA·Filed 1995·Granted Sep 25, 2001·35 cites·16 claims
- 2283US10370446B2Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathwayUNIV EMORY·Filed 2016·Granted Aug 6, 2019·3 cites·21 claims
- 2378US7153934B2T cell costimulatory polypeptides containing alternative domainsBRIGHAM & WOMENS HOSPITAL·Filed 2001·Granted Dec 26, 2006·2 cites·4 claims
- 2476US12186278B2Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapyNOVARTIS AG·Filed 2022·Granted Jan 7, 2025·0 cites·27 claims
- 2574US2020223926A1Compositions and methods for the treatment of infections and tumorsUNIV EMORY·Filed 2019·Application pending·0 cites
- 2673US11492403B2Anti-phosphotyrosinylated programmed death 1 (PD-1) monoclonal antibodies, methods of making and methods of using thereofDANA FARBER CANCER INST INC·Filed 2018·Granted Nov 8, 2022·1 cites·20 claims
- 2773US11359013B2Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathwayUNIV EMORY·Filed 2019·Granted Jun 14, 2022·0 cites·20 claims
- 2873US2021284737A1Antibody molecules to pd-l1 and uses thereofNOVARTIS AG·Filed 2020·Application pending·0 cites
- 2968US12258409B2Method of assessing the efficacy of a test agent for modulating programmed death 1 (PD-1) signaling by using anti-phosphotyrosinylated PD-1 monoclonal antibodiesDANA FARBER CANCER INST INC·Filed 2022·Granted Mar 25, 2025·0 cites·18 claims
- 3067US2023013364A1Combination therapies comprising antibody molecules to pd-1NOVARTIS AG·Filed 2021·Application pending·0 cites
- 3166US2025319179A1Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapyNOVARTIS AG·Filed 2025·Application pending·0 cites
- 3266US2004192899A1B-7 domain-specific antibodiesBRIGHAM & WOMENS HOSPITAL·Filed 2003·Application pending·0 cites
- 3365US11359020B2Agents that modulate immune cell activation and methods of use thereofDANA FARBER CANCER INST INC·Filed 2019·Granted Jun 14, 2022·0 cites·14 claims
- 3465US10927410B2Compositions and methods for identification, assessment, prevention, and treatment of T-cell exhaustion using CD39 biomarkers and modulatorsDANA FARBER CANCER INST INC·Filed 2015·Granted Feb 23, 2021·1 cites·7 claims
- 3565US2024018242A1Methods of treating cancer using lsd1 inhibitors in combination with immunotherapyCHILDRENS MEDICAL CENTER·Filed 2023·Application pending·0 cites
- 3664US2022041726A1Methods of reducing liver pd-1-expressing cd8+ t cells using pd-1 fc fusion proteins that bind fc receptorsDANA FARBER CANCER INST INC·Filed 2021·Application pending·0 cites
- 3764US2019330350A1Anti-pd-l1 monoclonal antibodies and fragments thereofDANA FARBER CANCER INST INC·Filed 2018·Application pending·0 cites
- 3864US2010040614A1Compositions and methods for the treatment of infections and tumorsAHMED RAFI·Filed 2007·Application pending·0 cites
- 3964US2022213212A1Methods and compositions for treating cancerHARVARD COLLEGE·Filed 2022·Application pending·0 cites
- 4064US2025230412A1Methods and compositions for treating cancerHARVARD COLLEGE·Filed 2023·Application pending·0 cites
- 4161US11028364B2Compositions and methods for modulating an immune responseHARVARD COLLEGE·Filed 2016·Granted Jun 8, 2021·0 cites·21 claims
- 4261US2022204604A1Methods and compositions for treating cancerHARVARD COLLEGE·Filed 2021·Application pending·0 cites
- 4360US2018155430A1Compositions and methods for the treatment of infections and tumorsUNIV EMORY·Filed 2017·Application pending·0 cites
- 4460US2022010275A1Compositions and methods for modulating an immune responsePRESIDENT AND FELLOWS OF HAVARD COLLEGE·Filed 2021·Application pending·0 cites
- 4560US2019031758A1Compositions and methods for the treatment of infections and tumorsUNIV EMORY·Filed 2018·Application pending·0 cites
- 4658US11124569B2Methods of reducing liver PD-1-expressing CD8+ T cells using PD-1 Fc fusion proteins that bind Fc receptorsDANA FARBER CANCER INST INC·Filed 2016·Granted Sep 21, 2021·0 cites·14 claims
- 4758US2012251537A1Compositions and methods for the treatment of infections and tumorsAHMED RAFI·Filed 2012·Application pending·0 cites
- 4855US2023340124A1Methods of treating an individual that has failed an anti-pd-1/anti-pd-l1 therapyHARVARD COLLEGE·Filed 2021·Application pending·0 cites
- 4953US10577586B2Compositions and methods for modulating an immune responseHARVARD COLLEGE·Filed 2018·Granted Mar 3, 2020·0 cites·15 claims
- 5052US2025352669A1Methods and compositions for treating cancers by modulating the expression and/or activity of stub1HARVARD COLLEGE·Filed 2025·Application pending·0 cites
Showing the top 50 of 61 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →